Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 2 Characteristics of individual studies included in the meta-analysis of PCSK9 E670G polymorphism and lipid levels

From: The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis

First author Year Country Ethnicity Type of study Subpopulation Genotype Number (n) TC (mmol/l) TG (mmol/l) HDL-C (mmol/l) LDL-C (mmol/l) Genotyping method
M SD M SD M SD M SD
Chen SN 1 [13] 2005 American Mixed Cohort LCAS population AA 324 5.69 0.62 1.83 0.64 1.14 0.29 3.72 0.51 Allelic discrimination assays
       AG + GG 48 5.82 0.66 1.66 0.63 1.16 0.31 3.89 0.57
Chen SN 2 [13] 2005 American Caucasian Cohort TexGen population AA 292 NA NA NA NA NA NA 2.28 0.65 Allelic discrimination assays
       AG + GG 27 NA NA NA NA NA NA 2.43 0.55
Evans D 1 [14] 2006 Germany Caucasian Cohort Male group AA 190 6.05 1.4 1.39 0.45 1.16 0.31 4.29 1.34 PCR-RFLP
       AG + GG 26 6.57 1.48 1.55 0.44 1.2 0.29 4.65 1.37  
Evans D 2 [14] 2006 Germany Caucasian Cohort Female group AA 210 6.83 1.45 1.32 0.45 1.55 0.44 4.65 1.45 PCR-RFLP
       AG + GG 18 6.65 1.47 1.22 0.23 1.58 0.52 4.5 1.37  
Scartezini M [15] 2007 UK Caucasian Cohort NPHSII men AA 930 5.73 0.99 NA NA 0.81 0.24 3.98 0.94 PCR-RFLP
       AG + GG 135 5.65 0.96 NA NA 0.83 0.26 3.92 0.94  
Polisecki E 1 [17] 2008 American Caucasian Cohort Male group AA 2455 5.25 0.03 NA NA NA NA 3.47 0.03 Taqman
       AG + GG 165 5.26 0.06 NA NA NA NA 3.47 0.06  
Polisecki E 2 [17] 2008 American Caucasian Cohort Female group AA 2638 5.71 1.73 NA NA NA NA 3.73 1.59 Taqman
       AG + GG 158 5.85 0.95 NA NA NA NA 3.84 0.84  
Hsu LA 1 [10] 2009 Taiwan Asian C-C CAD group AA 541 5.14 0.96 1.59 1.3 1.42 0.37 3.02 0.85 PCR-RFLP
       AG 73 4.95 0.96 1.72 1.53 1.44 0.36 2.78 0.82  
Hsu LA 2 [10] 2009 Taiwan Asian C-C Control group AA 182 5.29 1.31 2.32 2.07 1.04 0.27 3.25 1.17 PCR-RFLP
       AG 20 5.28 0.74 2.48 1.4 1.07 0.33 3.41 0.6  
Norata GD 1 [18] 2010 Italy Caucasian Cohort PLIC study AA 1466 5.71 0.98 1.2 0.79 1.42 0.38 3.74 0.9 Taqman
       AG + GG 75 5.99 1.2 1.16 0.58 1.45 0.35 4.01 1.07  
Norata GD 2 [18] 2010 Italy Caucasian Cohort Ventimiglia study AA 728 4.76 0.99 NA NA NA NA 3.02 0.86 Taqman
       AG + GG 48 4.89 0.98 NA NA NA NA 3.23 0.87  
Zeng J [19] 2011 China Asian C-C CAD group AA 167 3.73 0.8 1.5 0.59 1.26 0.38 2.16 0.73 PCR-RFLP
       AG + GG 45 4.25 1.38 1.87 1.16 1.26 0.41 2.58 1.08  
Meng YH [7] 2011 China Asian C-C CAD group AA 146 4.41 0.72 0.99 0.62 1.48 0.51 2.22 0.63 PCR-RFLP
       AG 19 4.63 1.21 1.17 0.97 0.98 0.84 3.02 0.97  
Aung LHH 1 [21] 2013 China Asian Cohort non-drinker group AA 744 4.59 0.99 1.23 0.92 1.82 0.49 2.55 0.82 PCR-RFLP
       AG 41 5.01 1.25 1.09 0.78 1.86 0.51 2.68 0.86  
Aung LHH 2 [21] 2013 China Asian Cohort Drinker group AA 543 4.84 1.07 1.02 0.73 1.74 0.44 2.94 0.81 PCR-RFLP
       AG 24 4.55 0.64 1.1 0.58 1.63 0.5 2.69 0.44  
Mayne J [20] 2013 Canada Caucasian Cohort African Canadian population AA 192 5.56 1.14 1.59 0.77 1.2 0.4 3.64 1.01 PCR + full exonic sequencing
       AG 15 5.11 1.12 1.27 0.48 1.1 0.3 3.45 1.11
Slimani A 1 [8] 2014 Tunisian African C-C CAD group AA 148 NA NA 1.69 0.86 1 0.36 NA NA PCR-RFLP
       AG + GG 44 NA NA 1.97 0.96 1.03 0.16 NA NA  
Slimani A 2 [8] 2014 Tunisian African C-C IS group AA 90 NA NA 1.58 0.75 1.35 0.4 NA NA PCR-RFLP
       AG + GG 24 NA NA 1.47 0.58 1.04 0.19 NA NA  
Anderson JM 1 [22] 2014 Brazil Caucasian C-C HC group AA 91 7.21 0.96 1.87 0.8 1.45 0.36 4.89 0.88 Taqman
       AG + GG 37 7.4 0.96 1.81 0.76 1.5 0.31 4.94 0.8  
Anderson JM 2 [22] 2014 Brazil Caucasian C-C NL group AA 131 4.47 0.47 0.91 0.32 1.53 0.36 2.53 0.47 Taqman
       AG + GG 40 4.5 0.49 0.95 0.3 1.47 0.26 2.59 0.47  
Zhang L 1 [23] 2014 China Asian C-C CAD group AA 291 4.07 1.16 1.82 0.79 1.37 0.16 2.29 0.77 PCR-RFLP
       AG + GG 125 4.49 1.31 1.87 1.09 1.31 0.25 2.5 0.74  
Zhang L 2 [23] 2014 China Asian C-C Control group AA 212 4.67 0.62 1.45 1.16 1.49 0.21 2.67 0.81 PCR-RFLP
       AG 45 4.53 0.33 1.37 0.88 1.4 0.21 2.63 0.8  
Jeenduang N 1 [24] 2015 Thai Asian Cohort Male group AA 132 5.54 1.3 1.46 0.84 1.32 0.35 3.66 1.13 PCR-RFLP
       AG 3 5.82 2.25 1.4 0.92 1.19 0.21 4 2.06  
Jeenduang N 2 [24] 2015 Thai Asian Cohort Female group AA 347 5.54 1.22 1.22 0.74 1.45 0.34 3.62 0.95 PCR-RFLP
       AG 13 5.99 0.94 1.01 0.35 1.49 0.23 4.04 0.94  
Mo YQ [26] 2015 China Asian C-C CAD group AA 87 4.48 0.81 0.97 0.58 1.49 0.47 2.12 0.72 DNA sequencing
       AG 13 4.56 0.97 1.05 0.89 0.97 0.73 3.01 0.83  
  1. C-C case–control, CAD coronary artery disease, IS ischemic stroke, NA not available, HC hypercholesterolemics, NL normolipidemics, UK United Kingdom, PCR-RFLP polymerase chain reaction- restriction fragment length polymorphism